Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 13, Issue 3, 2011, Pages 222-236

  Borchers, S ^a   Luther, S ^a   Lips, U ^a   Hahn, N ^a   Kontsendorn, J ^a   Stadler, M ^a   Buchholz, S ^a   Diedrich, H ^a   Eder, M ^a   Koehl, U ^b   Ganser, A ^a   Mischak Weissinger, Eva ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiviral immune reconstitution; CMV reactivation; Stem cell transplantation; Tetramer

Indexed keywords

BENZIMIDAVIR; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL MARKER; CIDOFOVIR; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; FOSCARNET; GANCICLOVIR; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHYCOERYTHRIN; STEROID; TETRAMER; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; BLOOD DONOR; CD8+ T LYMPHOCYTE; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HLA MATCHING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENT VIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR; SERODIAGNOSIS; STAINING; STEROID THERAPY; TETRAMER STAINING; VIRUS IMMUNITY; VIRUS REACTIVATION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PEPTIDES; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 79958002117     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00626.x     Document Type: Article

References (41)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2003; 9 (9): 543-558.
2. Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44 (8): 471-482.
3. Ganepola S, Gentilini C, Hilbers U, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39 (5): 293-299.
4. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65 (5): 432-436.
5. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101 (2): 407-414.
6. Einsele H, Hebart H. CMV-specific immunotherapy. Hum Immunol 2004; 65 (5): 558-564.
7. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis 2008; 40 (1): 71-75.
8. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001; 184 (8): 955-963.
9. Brooimans RA, Boyce CS, Popma J, et al. Analytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes. Cytometry A 2008; 73 (11): 992-1000.
10. Heijnen IA, Barnett D, Arroz MJ, et al. Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation. Cytometry B Clin Cytom 2004; 62 (1): 1-13.
11. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97 (5): 1232-1240.
12. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98 (5): 1358-1364.
13. Pastore D, Delia M, Mestice A, et al. Recovery of CMV-specific CD8(+) T cells and T regs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant Epub 7 May 2010.
14. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002; 100 (10): 3690-3697.
15. Chalandon Y, Degermann S, Villard J, et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006; 107 (1): 389-396.
16. Koehl U, Dirkwinkel E, Koenig M, et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 2008; 220 (6): 348-352.
17. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004; 78 (7): 1014-1020.
18. Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93 (2): 303-306.
19. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108 (3): 1092-1099.
20. Hauzenberger D, Schaffer M, Ringden O, et al. Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. Tissue Antigens 2008; 72 (6): 549-558.
21. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant 2004; 10 (2): 128-134.
22. Uzunel M, Remberger M, Sairafi D, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006; 82 (7): 913-919.
23. Moins-Teisserenc H, Busson M, Scieux C, et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008; 198 (6): 818-826.
24. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 2000; 6 (3): 280-288.
25. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102 (8): 3060-3067.
26. Schmitt A, Bechter C, Yao J, et al. Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem cell transplantation - validation of a peptide vaccine. J Immunol Methods 2009; 343 (2): 140-147.
27. Knabel M, Franz TJ, Schiemann M, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8 (6): 631-637.
28. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001; 98 (3): 505-512.
29. Watanabe N, Kamachi Y, Koyama N, et al. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes. Cytotherapy 2004; 6 (5): 514-522.
30. Rusakiewicz S, Aubert G, Clark RE, Madrigal AJ, Dodi AI, Travers PJ. Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses. Cancer Immunol Immunother 2009; 58 (9): 1459-1470.
31. Nakamura R, Battiwalla M, Solomon S, et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 2004; 10 (1): 49-57.
32. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40 (2): 125-136.
33. Chen FE, Aubert G, Travers P, Dodi IA, Madrigal JA. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 2002; 4 (1): 41-48.
34. Giest S, Grace S, Senegaglia AC, et al. Cytomegalovirus-specific CD8(+) T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. Br J Haematol 2010; 148 (1): 311-322. Epub 27 Oct 2009.
35. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201 (7): 1031-1036.
36. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and PP65-Specific CD4(+) and CD8(+) T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytom Part B-Clin Cy 2008; 74B (4): 211-220.
37. Ouyang Q, Wagner WM, Wikby A, et al. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 2003; 23 (4): 247-257.
38. Ouyang Q, Wagner WM, Voehringer D, et al. Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol 2003; 38 (8): 911-920.
39. Martino R, Caballero MD, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28 (4): 341-347.
40. Hill QA, Hill A, Collyns TA, Pearce RM, Cook G. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41 (8): 749-751.
41. Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007; 40 (2): 137-143.